摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-氯苯基)-1-甲基-1H-咪唑-2-硫醇 | 17452-31-2

中文名称
5-(4-氯苯基)-1-甲基-1H-咪唑-2-硫醇
中文别名
——
英文名称
5-(chlorophenyl)-1-methyl-1H-imidazole-2-thiol
英文别名
4-(p-Chlor-phenyl)-3-methyl-2-mercapto-imidazol;5-(4-chloro-phenyl)-1-methyl-1,3-dihydro-imidazole-2-thione;5-(4-chlorophenyl)-1-methyl-1H-imidazole-2-thiol;4-(4-chlorophenyl)-3-methyl-1H-imidazole-2-thione
5-(4-氯苯基)-1-甲基-1H-咪唑-2-硫醇化学式
CAS
17452-31-2
化学式
C10H9ClN2S
mdl
MFCD01313844
分子量
224.714
InChiKey
RGYNOPLNIDBIGT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    244 °C

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    47.4
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933290090

SDS

SDS:f3c2fc11dd9d2b7ea3c44505a4dcebf9
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR MODIFIER L'ACTIVITÉ DE GSK-3
    申请人:UNIV OHIO
    公开号:WO2016010611A1
    公开(公告)日:2016-01-21
    Methods for modulating GSK-3 activity and methods for treating a GSK-3 -mediated disorder in a subject in need thereof. The methods include contacting a cell expressing GSK-3 with or administering to the subject in need a therapeutically effective amount of one or more compounds of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof.
    调节GSK-3活性的方法和治疗需要的主体中GSK-3介导的疾病的方法。该方法包括将表达GSK-3的细胞与或向需要的主体施用一种或多种通用式(I)或通用式(II)的化合物的治疗有效量接触,或其药用接受的盐或溶剂。
  • CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS
    申请人:Catalano George John
    公开号:US20080058333A1
    公开(公告)日:2008-03-06
    Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.
    本文描述了环状烷基酮酰胺衍生物,其作为猫hepsin K抑制剂具有用途。所述发明还包括制备这种环状烷基酮酰胺衍生物的方法,以及使用它们治疗与增强骨转换相关的疾病的方法,包括骨质疏松症,最终可能导致骨折。
  • 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
    申请人:MAUGER Jacques
    公开号:US20080261969A1
    公开(公告)日:2008-10-23
    This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
    本发明涉及式(I)化合物、制备该类化合物的方法、包含该类化合物的药物组合物,以及通过给予该类化合物的治疗方法。
  • Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
    申请人:SmithKline Beecham Corporation
    公开号:US07282512B2
    公开(公告)日:2007-10-16
    Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.
    本文描述了用作cathepsin K抑制剂的环状酰胺衍生物。所述的发明还包括制备这种环状酰胺衍生物的方法,以及在治疗与增强骨转换有关的疾病,包括骨质疏松症,最终可能导致骨折的方法。
  • Imidazole and thiazole compositions for modifying biological signaling
    申请人:Ohio University
    公开号:US10023567B2
    公开(公告)日:2018-07-17
    Compounds having General Formula (I) or General Formula (II): in which R1 is chosen from C1 to C10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof; R2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties substituted heteroaromatic moieties, and coumarin; R3 is chosen from —H, C1 to C10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.
    具有通式(I)或通式(II)的化合物:其中 R1 选自 C1 至 C10 脂肪族或杂脂肪族基团,任选被一个或多个芳基、取代芳基、杂芳基、取代杂芳基或其组合取代;R2 选自芳香族基团、取代芳香族基团、杂芳香族基团、取代杂芳香族基团和香豆素;R3 选自-H、C1 至 C10 脂肪族或杂脂肪族基团、苯基或取代苯基,其中脂肪族或杂脂肪族基团可选择被一个或多个苯基、芳基、杂芳基、取代杂芳基或其组合取代,并且其中脂肪族或杂脂肪族基团可选择与 R2 键合形成环;X 是 S 或 O;Y 是 S 或 NH,可用于改变生物信号转导过程的药物组合物或用作生物检测试剂。
查看更多